spec sheet10 rows
LAE-32, or lysergic acid monoethylamide, is a lysergamide closely related to LSD in which one of the two ethyl groups of the diethylamide is removed, leaving a single ethylamide. It retains activity at serotonin receptors and is psychoactive, but historical human and animal studies from the 1950s reported it to be substantially less potent than LSD and more sedating or dreamy in character rather than strongly hallucinogenic. The same monoethylamide also appears as a minor metabolite of LSD, detectable at trace levels in plasma after controlled LSD administration. Owing to its early characterization and limited use, the modern literature on LAE-32 is sparse and consists largely of these mid-twentieth-century comparisons with LSD.
- Milder, more manageable than LSD
- Dreamy, sedative quality
- Lysergamide character at lower intensity
- Sedating single-ethyl lysergamide analog of LSD
- Sedation and grogginess
- Vasoconstriction
- Nausea possible
Mechanism
LAE-32 works as an at the receptor, the receptor tied to the psychedelic state, but dropping one ethyl group from LSD's amide greatly reduces its affinity and potency. The result is a comparatively weak lysergamide with a more sedative, less sharply psychedelic character. Its overall receptor profile is only loosely characterized.
receptor fingerprint
receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
LAE-32 is much weaker than LSD but is still an active lysergamide and poorly studied. Avoid with a personal or family history of psychosis or bipolar disorder, and never combine lysergamides with MAOIs or strongly serotonergic drugs (serotonin toxicity), or with lithium or tramadol (seizure reports). Not medical advice.
Subjective profileweighing the evidence above
Mostly a historical curiosity. Dropping one ethyl group from LSD costs most of the potency and swaps clarity for sedation and grogginess, which is not an improvement on anything, and there is very little formal study behind it.
Resources
This entry is here for reference.
Research
- 1955first cited[Psychological effects of lysergic acid monoethylamide (LAE 32)].
- 2018most recentDevelopment and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD),…
- 1.Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent.
- 2.[Psychological effects of lysergic acid monoethylamide (LAE 32)].
- 3.Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.
- 4.[Effect of psilocybin on the behavior of normal mice & waltzing mice; comparison with lysergic acid monoethylamide & diethylamide].
- 5.[Study of the antagonistic psychopathological effects of lysergic acid monoethylamide (LAE-32) & methylphenylisopropylamine (pervitin)].
- 6.[Effect of monoethylamide (LAE) and diethylamide (LSD) of lysergic acid on behavior of mouse with imino-beta,beta-dipropionitrile induced circular movement].
6 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
How does LAE-32 compare to LSD?
It is a much weaker relative, generally described as more sedating and dreamy rather than sharply psychedelic.
Why is it weaker?
Removing one of LSD's two ethyl groups from the amide sharply cuts its 5-HT2A activity.
Is it common?
No; it is a rare, historical lysergamide with little modern data. This is not medical advice.
Adverse effects
- Sedation and grogginess
- Vasoconstriction
- Nausea possible
Notes and cautions
- Poorly characterized